NH House Testimony

HB1772

House · 2026 sessionRepublicanSigned into law

Ibogaine research and PA licensing compact

AI

Permits licensed health care providers to administer ibogaine for investigational use under an FDA-approved research protocol and adopts the physician associate licensure compact.

(Second New Title) relative to prescribing ibogaine for investigational use only and adopting the physician associate licensure compact.

Public and Mental HealthOccupational Regulation

Status

Signed into law · July 20, 2026
  1. Introduced
  2. House
  3. Senate
  4. Governor
  5. Law

Division of testimony

27 submissions
Support 5Oppose 19Neutral 3
Margaret KonzeSupportPembroke, NHfor MyselfFeb 24, 2026

When I studied addition treatments back in the early 90s this was mentioned as an option for treating opioid addiction and crack addiction, which is interesting because there isn’t MAT for cocaine abuse that I am aware of. I didn’t realize it has since been banned until just now. A quick internet search shows that Sanford states it’s useful for TBIs and PTSD as well. https://med.stanford.edu/news/all-news/2024/01/ibogaine-ptsd.html

Tami Lanzillo ZeimetzOpposeGilford, NHfor MyselfFeb 24, 2026

After reviewing several articles, it appears that this drug needs to have more testing before it is an accepted treatment.

Daniel RichardsonOpposeNashua, NHfor MyselfFeb 24, 2026

The last thing needed for mental health is dosing with hallucinogenic drugs. Ibogaine is a psychoactive indole alkaloid derived from plants such as Tabernanthe iboga, characterized by hallucinogenic and oneirogenic effects. The psychoactivity of the root bark of the iboga tree, T. iboga, one of the plants from which ibogaine is extracted, was first discovered by forager tribes in Central Africa, who passed the knowledge to the Bwiti tribe of Gabon. It was first documented in the 19th century for its spiritual use, later isolated and synthesized for its psychoactive properties..

Cynthia WhitakerOpposeWeare, NHfor MyselfFeb 24, 2026

This legislation raises serious concerns not about the promise of ibogaine research itself, but about the appropriateness of state government as a vehicle for that research. The bill's own eligibility criteria make clear that any qualifying institution would already possess substantial research infrastructure, federal IND application status, FDA breakthrough therapy designation pursuit, and multi-state consortium partnerships. In other words, the entities capable of receiving these grants are already doing this work, already embedded in the federal research process, and already securing funding from non-state sources. This raises a straightforward question: if the research is already moving forward through the institutions and federal mechanisms designed for exactly this purpose, what does state money add, beyond state liability? Meanwhile, the Department of Health and Human Services faces significant and well-documented unmet needs across behavioral health, substance use treatment access, child welfare, and long-term care — areas where state dollars have a direct and immediate impact on New Hampshire residents. Redirecting or reserving agency capacity and public funds for a research function that credentialed institutions and federal oversight bodies are already managing is difficult to justify on either fiscal or programmatic grounds. The state legislature's most responsible role here is to trust the scientific process already underway — not to insert the state into it with public dollars and the legal exposure that follows. A vote of Inexpedient to Legislate is the appropriate outcome: not a rejection of the science, but a recognition that this is not the state's work to do.

CORY STONESupportDover, NHfor MyselfFeb 23, 2026

Ibogaine has many benefits with practically no side effects when administered by a professional. Please support this bill so help so many Americans quickly with lasting effects.

Julia MeadOpposeConcord, NHfor MyselfFeb 24, 2026

Position recorded without written comment.

Frank MullerOpposeConcord, NHfor MyselfFeb 24, 2026

Position recorded without written comment.

Katharine FoxOpposeConcord, NHfor MyselfFeb 24, 2026

Position recorded without written comment.

Emily ZajanoOpposeExeter, NHfor MyselfFeb 24, 2026

Position recorded without written comment.

Michele ChaliceOpposeKeene, NHfor MyselfFeb 24, 2026

Position recorded without written comment.

Diane RamusOpposeLee, NHfor MyselfFeb 24, 2026

Position recorded without written comment.

Kristin VaughanOpposeExeter, NHfor MyselfFeb 24, 2026

Position recorded without written comment.

Danielle AlbushiesOpposeBow, NHfor MyselfFeb 24, 2026

Position recorded without written comment.

Marcia ArsnowOpposeWolfeboro, NHfor MyselfFeb 24, 2026

Position recorded without written comment.

Sue HomolaOpposeHollis, NHfor MyselfFeb 24, 2026

Position recorded without written comment.

Zachary FedericoNeutralArlington, VAfor American Legislative Exchange CouncilFeb 24, 2026

Position recorded without written comment.

Geoffrey LawrenceSupportWashington, DCfor Reason FoundationFeb 24, 2026

Position recorded without written comment.

Jessica HarrisOpposeRumney, NHfor MyselfFeb 24, 2026

Position recorded without written comment.

Susan FanburgOpposeBedford, NHfor MyselfFeb 24, 2026

Position recorded without written comment.

Cathy MayneSupportHenniker, NHfor MyselfFeb 24, 2026

Position recorded without written comment.

Katie McLaughlinOpposeWeare, NHfor MyselfFeb 24, 2026

Position recorded without written comment.

Ann GarlandOpposeLEBANON, NHfor MyselfFeb 24, 2026

Position recorded without written comment.

Mara PerryOpposeExeter, NHfor MyselfFeb 23, 2026

Position recorded without written comment.

Jennifer O'HigginsNeutralNew Hampshire, NHfor DHHSFeb 23, 2026

Position recorded without written comment.

Sue HolsteinOpposeBedford, NHfor MyselfFeb 23, 2026

Position recorded without written comment.